Journal article
Successful renal denervation decreases the platelet activation status in hypertensive patients
MTK Zaldivia, D Hering, P Marusic, Y Sata, R Lee, MD Esler, NM Htun, J Duval, L Hammond, U Flierl, X Wang, GR Drummond, A Walton, EE Gardiner, RK Andrews, MP Schlaich, K Peter
Cardiovascular Research | OXFORD UNIV PRESS | Published : 2020
DOI: 10.1093/cvr/cvz033
Abstract
Aims: To determine whether renal denervation (RDN) in hypertensive patients affects the platelet activation status. Methods and results: We investigated the effect of RDN on the platelet activation status in 41 hypertensive patients undergoing RDN. Ambulatory blood pressure (BP), plasma sympathetic neurotransmitter Neuropeptide Y, and platelet activation markers were measured at baseline, at 3 months, and 6 months after RDN. RDN significantly decreased BP at 3 months (150.6 ± 11.3/80.9 ± 11.4 mmHg to 144.7 ± 12.0/77.1 ± 11.1 mmHg; P < 0.01) and at 6 months (144.3 ± 13.8/78.3 ± 11.1 mmHg; P < 0.01). Plasma levels of the sympathetic neurotransmitter Neuropeptide Y, an indicator of sympathetic ..
View full abstractGrants
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia; M.D.E., E.E.G., M.P.S. and K.P. were supported by NHMRC Research Fellowships. X.W. was supported by a National Heart Foundation Fellowship.